Henan Lingrui Pharmaceutical Co Ltd (600285) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Henan Lingrui Pharmaceutical Co Ltd (600285) has a cash flow conversion efficiency ratio of 0.043x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥140.12 Million ≈ $20.50 Million USD) by net assets (CN¥3.28 Billion ≈ $480.45 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Henan Lingrui Pharmaceutical Co Ltd (600285) market capitalisation for the company's overall valuation and market capitalisation.
Henan Lingrui Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Henan Lingrui Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Henan Lingrui Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Henan Lingrui Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Explore 600285 cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HBIS Resources Co Ltd
SHE:000923
|
0.010x |
|
Changchun UP Optotech Co Ltd
SHE:002338
|
-0.016x |
|
Jiangsu Expressway Company Limited
F:JE2
|
0.035x |
|
Suning Commerce Group Co Ltd
SHE:002024
|
0.015x |
|
Siloam International Hospitals
JK:SILO
|
0.027x |
|
Kernel Holding SA
WAR:KER
|
-0.080x |
|
Shinkong Insurance Co Ltd
TW:2850
|
0.144x |
|
Kansai Nerolac Paints Limited
NSE:KANSAINER
|
0.031x |
Annual Cash Flow Conversion Efficiency for Henan Lingrui Pharmaceutical Co Ltd (1999–2025)
The table below shows the annual cash flow conversion efficiency of Henan Lingrui Pharmaceutical Co Ltd from 1999 to 2025. View 600285 stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥3.44 Billion ≈ $502.78 Million |
CN¥553.88 Million ≈ $81.05 Million |
0.161x | -43.31% |
| 2024-12-31 | CN¥3.08 Billion ≈ $450.74 Million |
CN¥875.86 Million ≈ $128.17 Million |
0.284x | -2.17% |
| 2023-12-31 | CN¥2.80 Billion ≈ $409.54 Million |
CN¥813.43 Million ≈ $119.03 Million |
0.291x | -10.94% |
| 2022-12-31 | CN¥2.56 Billion ≈ $374.38 Million |
CN¥834.91 Million ≈ $122.17 Million |
0.326x | -11.77% |
| 2021-12-31 | CN¥2.29 Billion ≈ $334.60 Million |
CN¥845.69 Million ≈ $123.75 Million |
0.370x | +90.63% |
| 2020-12-31 | CN¥2.32 Billion ≈ $339.80 Million |
CN¥450.53 Million ≈ $65.93 Million |
0.194x | -4.30% |
| 2019-12-31 | CN¥2.22 Billion ≈ $324.92 Million |
CN¥450.15 Million ≈ $65.87 Million |
0.203x | -2.67% |
| 2018-12-31 | CN¥2.09 Billion ≈ $306.49 Million |
CN¥436.25 Million ≈ $63.84 Million |
0.208x | +333.20% |
| 2017-12-31 | CN¥2.20 Billion ≈ $322.52 Million |
CN¥105.97 Million ≈ $15.51 Million |
0.048x | +60.53% |
| 2016-12-31 | CN¥2.11 Billion ≈ $309.08 Million |
CN¥63.26 Million ≈ $9.26 Million |
0.030x | -67.07% |
| 2015-12-31 | CN¥1.72 Billion ≈ $252.28 Million |
CN¥156.82 Million ≈ $22.95 Million |
0.091x | +14.19% |
| 2014-12-31 | CN¥1.56 Billion ≈ $228.39 Million |
CN¥124.32 Million ≈ $18.19 Million |
0.080x | -38.36% |
| 2013-12-31 | CN¥984.89 Million ≈ $144.12 Million |
CN¥127.27 Million ≈ $18.62 Million |
0.129x | +483.53% |
| 2012-12-31 | CN¥696.97 Million ≈ $101.99 Million |
CN¥15.43 Million ≈ $2.26 Million |
0.022x | -62.59% |
| 2011-12-31 | CN¥684.01 Million ≈ $100.09 Million |
CN¥40.49 Million ≈ $5.92 Million |
0.059x | +1163.14% |
| 2010-12-31 | CN¥709.69 Million ≈ $103.85 Million |
CN¥-3.95 Million ≈ $-578.20K |
-0.006x | -102.71% |
| 2009-12-31 | CN¥645.69 Million ≈ $94.48 Million |
CN¥132.61 Million ≈ $19.40 Million |
0.205x | +158.23% |
| 2008-12-31 | CN¥549.72 Million ≈ $80.44 Million |
CN¥43.72 Million ≈ $6.40 Million |
0.080x | +188.20% |
| 2007-12-31 | CN¥579.24 Million ≈ $84.76 Million |
CN¥15.99 Million ≈ $2.34 Million |
0.028x | -49.82% |
| 2006-12-31 | CN¥486.67 Million ≈ $71.21 Million |
CN¥26.76 Million ≈ $3.92 Million |
0.055x | -21.07% |
| 2005-12-31 | CN¥479.80 Million ≈ $70.21 Million |
CN¥33.43 Million ≈ $4.89 Million |
0.070x | -7.89% |
| 2004-12-31 | CN¥469.45 Million ≈ $68.70 Million |
CN¥35.51 Million ≈ $5.20 Million |
0.076x | +43.63% |
| 2003-12-31 | CN¥451.69 Million ≈ $66.10 Million |
CN¥23.79 Million ≈ $3.48 Million |
0.053x | -68.38% |
| 2002-12-31 | CN¥416.74 Million ≈ $60.98 Million |
CN¥69.41 Million ≈ $10.16 Million |
0.167x | +1861.90% |
| 2001-12-31 | CN¥401.79 Million ≈ $58.79 Million |
CN¥3.41 Million ≈ $499.14K |
0.008x | -5.34% |
| 2000-12-31 | CN¥408.46 Million ≈ $59.77 Million |
CN¥3.66 Million ≈ $536.06K |
0.009x | -88.42% |
| 1999-12-31 | CN¥62.08 Million ≈ $9.08 Million |
CN¥4.81 Million ≈ $703.65K |
0.077x | -- |
About Henan Lingrui Pharmaceutical Co Ltd
Henan Lingrui Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China. It operates through Pharmaceutical and Healthcare Division; and Others segments. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, and tinctures, etc. for various indications, including orth… Read more